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Usher syndrome (USH), the most prevalent cause of hereditary deafness–blindness, is an autosomal recessive and genetically
heterogeneous disorder. Three clinical subtypes (USH1–3) are distinguishable based on the severity of the sensorineural hearing
impairment, the presence or absence of vestibular dysfunction, and the age of onset of the retinitis pigmentosa. A total of
10 causal genes, 6 for USH1, 3 for USH2, and 1 for USH3, and an USH2 modiﬁer gene, have been identiﬁed. A robust molecular
diagnosis is required not only to improve genetic counseling, but also to advance gene therapy in USH patients. Here, we present an
improved diagnostic strategy that is both cost- and time-effective. It relies on the sequential use of three different techniques to
analyze selected genomic regions: targeted exome sequencing, comparative genome hybridization, and quantitative exon ampliﬁcation.
We screened a large cohort of 427 patients (139 USH1, 282 USH2, and six of undeﬁned clinical subtype) from various European
medical centers for mutations in all USH genes and the modiﬁer gene. We identiﬁed a total of 421 different sequence variants
predicted to be pathogenic, about half of which had not been previously reported. Remarkably, we detected large genomic
rearrangements, most of which were novel and unique, in 9% of the patients. Thus, our strategy led to the identiﬁcation of biallelic
and monoallelic mutations in 92.7% and 5.8% of the USH patients, respectively. With an overall 98.5% mutation characterization
rate, the diagnosis efﬁciency was substantially improved compared with previously reported methods.
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INTRODUCTION
Usher syndrome (USH) is an autosomal recessive disease, accounting
for about half of all cases of combined hereditary deafness–blindness.
The prevalence of USH has been estimated to be between 1/6000 and
1/25 000.1,2 USH is clinically and genetically heterogeneous. Three
clinical subtypes (USH1–3) are distinguishable based on the severity of
the hearing impairment, the presence or absence of vestibular
dysfunction, and the age of onset of the retinitis pigmentosa associated
with the visual deﬁcit.3 USH1, the most severe form, results from
mutations in any of at least six different genes: MYO7A (MIM
276900), USH1C (MIM 276904), CDH23 (MIM 601067), PCDH15
(MIM 602083), USH1G (MIM 606943), and CIB2 (MIM 614869),
encoding the actin-based motor protein myosin VIIa (USH1B), the
transmembrane proteins cadherin-23 (USH1D) and protocadherin-15
(USH1F), the submembrane scaffold proteins harmonin (USH1C)
and sans (USH1G), and the calcium-integrin-binding protein CIB2
(USH1J), respectively. There are three known USH2 genes: USH2A
(MIM 276901), ADGRV1 (formerly known as VLGR1 or GPR98,
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MIM 605472), and DFNB31 (MIM 611383), encoding the large
transmembrane proteins usherin (USH2A) and adhesion G-protein-
coupled receptor V1 (USH2C), and the submembrane scaffold protein
whirlin (USH2D), respectively. In addition, PDZD7, encoding a PDZ-
domain-containing scaffold protein similar to whirlin and harmonin,
is a modiﬁer gene for the retinal phenotype in patients with biallelic
mutations in USH2A, and contributes to digenic inheritance with
ADGRV1.4 Only one USH3 gene has been identiﬁed so far, CLRN1
(USH3A, MIM 276602), encoding the transmembrane protein clarin-
1. Albeit controversial, a fourth clinical subtype has recently been
proposed, which regroups atypical forms of USH such as those
resulting from mutations of CEP250, HARS, or ABHD12, encoding
a centrosomal core protein, an amino acyl tRNA synthetase, and a
serine hydrolase, respectively.5–7
USH1 accounts for ~ 35% of USH cases.8 The main ﬁve genes
implicated in USH1 are MYO7A (53–73%), CDH23 (7–20%),
PCDH15 (7–12%), USH1C (1–15%), and USH1G (0–4%),9–11
whereas only one USH1J family with a CIB2 mutation has been
identiﬁed so far.12 USH2, the most frequent USH clinical subtype,
accounts for about two-thirds of all reported USH cases.13 Mutations
in USH2A, ADGRV1, and DFNB31 have been identiﬁed in 58–90,
5–19, and 0–9.5% of USH2 patients, respectively, depending on the
population studied.9,10,14 Only 3% of USH patients are classiﬁed as
USH3 in most populations,15 except in the Finnish and Ashkenazi
Jewish populations: in these populations USH3A accounts for almost
40% of all USH cases.16,17
There are ongoing efforts to ﬁnd an efﬁcient method for reliable
molecular diagnosis of USH. This is essential not only for genetic
counseling but also for the development of gene therapy. Genotyping
initially focused on a set of single-nucleotide polymorphisms (SNPs)
known to be associated with USH, using methods such as arrayed
primer extension microarrays. This approach, however, only identiﬁed
biallelic mutations in about a third of the patients,18 which is
consistent with the high genetic heterogeneity of USH. To extend
the search for sequence variations, we and others then used direct
Sanger sequencing to analyze all coding exons and neighboring
intronic sequences of USH genes. This allowed the identiﬁcation of
the two causal mutations in ~ 70% of patients.9,10,14,19–21 However,
this approach was time- and cost-consuming because of the large
number of exons to be surveyed (~400).9,10 The use of next-
generation sequencing techniques, which allow to analyze either the
entire exome, or a subset of it, has improved considerably the time-
and cost-effectiveness of the molecular diagnosis of USH. The
diagnosis efﬁciency, however, remained ~ 70% when these techniques
were used on their own.22–24 We report here an innovative strategy to
identify both short DNA sequence variations and copy number
variations (CNVs) using a combinatorial approach. Short DNA
sequence variants were identiﬁed by high-throughput sequencing of
a targeted panel of multiplexed amplicons, and CNVs were identiﬁed
using genome-wide SNP arrays and exon-speciﬁc quantitative real-
time polymerase chain reactions (qPCR). This enabled us to substan-
tially improve the efﬁciency of the molecular diagnosis of USH
without signiﬁcantly increasing the associated time and cost.
PATIENTS AND METHODS
This study was approved by the local ethics committees, and was carried out
following the ethical principles for medical research involving human subjects
deﬁned by the WMA Declaration of Helsinki.
Patients
A total of 427 USH patients were recruited between 2011 and 2015, from six
European countries: France (194), Germany (86), Italy (62), Slovenia (61),
Spain (21), and Denmark (three). The clinical diagnosis of USH was based on
evidence of sensorineural deafness and concurrent retinal degeneration
indicative of retinitis pigmentosa. We further classiﬁed the patients into USH
subtypes based on the results of pure tone audiometry, ocular fundus
autoﬂuorescence, and electroretinogram, as well as the presence or absence
of a balance defect, manifested in young children by a delay in the ability to sit
and walk independently.25 All the medical centers shared the same protocol for
clinical evaluation of the patients. Patients matching the criteria for the study
were enrolled in the cohort once they had agreed (either directly or through
their legal representative if underage) to sign an informed consent form and to
provide a blood sample for genetic testing. Blood samples from the patient’s
mother and father were also collected for segregation analysis whenever possible
(ie, in ~ 45% of the cases). Genomic DNA was extracted according to standard
procedures. DNA extraction was performed either on site, or after shipment of
the blood samples to the research laboratory at the Vision Institute in Paris
(France), where all the DNA samples were later processed and analyzed.
Targeted exome sequencing (TES) and bioinformatic analysis
A multiplex amplicon panel (Fluidigm Access Array) was created to analyze all
coding and non-coding exons of the 10 USH genes and the USH2 modiﬁer
gene PDZD7.4 Exons recently identiﬁed by retina-speciﬁc transcript analysis
were included.26 The amplicons also covered a minimum of 25-bp intronic
sequence ﬂanking each exon to facilitate the detection of sequence variants
that affect splice sites. The USH2A intronic region harboring the mutation
c.7595-2144A4G was also included.27 The primers were designed based on the
design program Primer3.28,29 A total of 1268 primer pairs (sequences available
on request) were chosen to produce amplicons with an average length of
165 bp. Forty-eight pools of primer pairs were created such that each primer
pair was represented twice per assay in independent pools, and each pool of
primers contained a unique combination of 47–48 different primer pairs.
Following the preparation of the multiplexed amplicon libraries, samples
with a minimum of 1 μg of double-stranded DNA, as determined using the
SYBR Green I ﬂuorescent double-strand method (Life Technologies, Foster city,
CA, USA), were puriﬁed using the Agencourt AMPure XP kit (Beckman
Coulter Inc., Fullerton, CA, USA). We used an Access Array microﬂuidic
support (Fluidigm, San Francisco, CA, USA) to perform 48 independent PCR
reactions in parallel, on 48 different samples at once (ie, a total of 2304 distinct
amplicons). We increased the capacity of the device to 110 592 simultaneous
PCR reactions per run by optimizing the PCR mix and primer pools to allow
multiplexed ampliﬁcation in each PCR slot. This made it possible to
simultaneously produce 2304 amplicons for each of the 48 samples.
During the ﬁrst PCR on the Access Array, a universal tag present at the
5′ end of each primer (Rd1 Tag on the forward primer and Rd2 Tag on the
reverse primer) was added to the extremities of each amplicon. Following
thermocycling of the Access Array on the BioMark, the Access Array was
transferred to the Post-PCR IFC Controller AX (Fluidigm) to recover the 48
pooled PCRs for each sample. The pooled amplicons were then puriﬁed with
Agencourt AMPure XP beads and subjected to a second round of PCR, using
the universal tags added during the ﬁrst PCR round as templates. Samples from
two distinct Access Arrays were processed at once and subjected to six cycles of
ampliﬁcation in a standard microplate format. This second ampliﬁcation round
was used to add a speciﬁc identiﬁcation barcode to each sample, as well as P5
and P7 adapters for sequencing purposes. Each PCR was then controlled on a
Fragment Analyzer (AATI, Ankeny, IA, USA), and quantiﬁed to create an
equimolar pool of the 96 samples. This pool was again puriﬁed with AMPure,
and loaded onto a Fragment Analyzer or Bioanalyzer (Agilent, Santa Clara, CA,
USA) to verify the proﬁle by comparing it with the expected proﬁle. This pool
was sequenced on a HiSeq 2000 sequencer (Illumina, San Diego, CA, USA). For
each sample, a total of 313 Mb reads were sequenced per 108 kb of analyzed
genome, which represents a 2900× coverage.
Raw sequencing data were processed for bioinformatics analysis through the
Illumina pipeline (CASAVA1.8.2), using the ELANDv2 algorithm for sequence
alignment (multiseed and gapped) and the sequence of each amplicon as
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reference. Variants were called if they met the following criteria: (1) a read
depth superior to ﬁve with no ambiguous reading, and (2) an allelic frequency
inferior to 0.3% in all the following public variant databases: dbSNP132,
Hapmap, 1000 Genomes, Exome Variant Server, Exome Aggregation Con-
sortium (http://exac.broadinstitute.org/), Usher-speciﬁc Leiden Open
Variation Database(https://grenada.lumc.nl/LOVD2/Usher_montpellier/home.
php), and Deafness Variation Database (http://deafnessvariationdatabase.org/).
They were then ranked according to their expected negative impact on the
resulting gene product. Nonsense variants and small deletions or insertions
inducing a frameshift of the coding sequence were considered the most
damaging, as they necessarily alter the amino-acid sequence of the protein. The
pathogenicity of missense and splice-site variants was estimated using the
following prediction algorithms: PolyPhen2, SIFT, and Mutation Taster for
missence variants, and NNSplice, ESEﬁnder, Max Ent Scan, Gene Splicer, and
Human Splicing Finder for splice-site variants. From those sequence variants
predicted to be highly damaging, pathogenic, and/or disease-causing, candidate
variants were chosen if they were biallelic and/or lying within genes matching
with the clinical diagnosis. Their presence was conﬁrmed in the patient's and,
whenever possible, the parents' DNAs, by Sanger sequencing using standard
protocols. The entire process, from library preparation to variant identiﬁcation,
took 3–4 weeks for 48 patients.
Comparative genome hybridization (CGH) using SNP arrays
CytoSNP-12 arrays (Illumina, San Diego, CA, USA), which contain 300 000
polymorphic markers including 200 000 SNPs spread throughout the human
genome, were used to assess the zygosity of USH genes in patients, when no
mutation or only a monoallelic mutation was detected by TES. The samples
were processed using the Inﬁnium assay as previously described30 and the
results analyzed using Illumina Genome Studio software. An internal reference
was created using the clustering algorithm Illumina Gentrain 2.0 on the SNP
proﬁles from 96 samples that were processed during the same run. The SNP
proﬁles were analyzed by comparing the log R ratio (where the R ratio is the
sample copy number over the reference copy number) and B allele frequency
(BAF). CNV was identiﬁed by the sign of the log R ratio. A positive value
indicated a duplication and a negative value a deletion. The genotype of each
SNP was inferred from the value of its BAF, BAF= 0 indicating two copies
identical to the reference genome (hg19), whereas BAF= 1 signaled two copies
of the variant sequence and BAF= 0.5, a SNP at the heterozygous state.
qPCR analysis
Quantitative real-time PCR was performed using a SYBR Green PCR master
mix (Applied Biosystems, Foster city, CA, USA) and speciﬁc primers were
designed using the program Primer3,28,29 such that the amplicon length did not
exceed 200 bp (primer sequences available on request). The PCR reactions were
performed in duplicate using two different amounts of genomic DNA (10 ng
and 2 ng, in 5 μl) in a ﬁnal volume of 20 μl, including 0.2 μl of each primer
(20 μM ﬁnal concentration), 4.6 μl of nuclease free water, and 10 μl of power
SYBR Green PCR master mix. Positive and negative (no DNA template)
controls were used in each run. PCR ampliﬁcation was performed in a 96-well
plate format on a 7500 Fast Real-Time PCR machine (Applied Biosystems)
using the following conditions: 2 min at 50 °C, 10 min at 95 °C, 40 cycles (15 s
at 95 °C and 1 min at 60 °C), 15 s at 95 °C, 1 min at 60 °C, and 15 s at 95 °C.
The ﬁnal dissociation step was included at the end of the PCR program to
generate melting curves and assess primer speciﬁcity.31 Relative quantiﬁcation
was performed using the ΔΔCT method to normalize the number of USH gene
copies to those of the housekeeping gene GAPDH.32,33
Reference sequences for mutation nomenclature and exon
numbering
In this article, the nomenclature of all sequence variants and exon numbering
refer to the following genomic and cDNA reference sequences [NG_ and NM_
NCBI accession numbers, respectively]: MYO7A [NG_009086.1, NM_000
260.3]; USH1C [NG_011883.1, NM_153676.3]; CDH23 [NG_008835.1,
NM_022124.5]; PCDH15 [NG_009191.1, NM_001142769.1 (CD2.1 transcript)];
USH1G [NG_007882.1, NM_173477.4]; CIB2 [NG_033006.1, NM_001301224.1];
USH2A [NG_009497.1, NM_206933.2]; ADGRV1 [NG_007083.1,
NM_032119.1]; WHRN/DFNB31 [NG_016700.1, NM_015404.3]; PDZD7
[NG_028030.1, NM_001195263.1]; USH3A [NG_009168.1, NM_174878.2
(transcript a), NM_052995.2 (transcript c)].
All pathogenic or presumably pathogenic variants identiﬁed in the USH
genes have been deposited in the ‘Leiden Open Variation Database'.
RESULTS AND DISCUSSION
TES identiﬁes biallelic and monoallelic short sequence variants
predicted to be pathogenic in 85% and 12% of USH patients,
respectively
TES of the 10 USH genes (6 for USH1, 3 for USH2, 1 for USH3) and
the USH2 modiﬁer gene PDZD7 was carried out. The PCR primers
were chosen to allow the multiplex ampliﬁcation of all known exons
of the paneled genes, as well as their ﬂanking intronic sequences (see
Patients and Methods for details). A total of 398 exons of interest,
representing 108 kb of cumulated genomic sequence, were thus
scanned for point mutations and short (o20 bp) deletions or
insertions.
First, we validated this TES technique on 12 USH patients
previously diagnosed with biallelic point mutations,10 and were able
to identify all the mutations. We then proceeded to the analysis of a
large cohort of 427 clinically deﬁned USH patients, which was
established through a collaborative, multicentric initiative involving
six European countries: Denmark, France, Germany, Italy, Slovenia,
and Spain. For each patient, a list of small sequence variants that were
rarely encountered in the general population (allelic frequency inferior
to 0.3%) was established (see Patients and Methods for details). This
list was then sorted according to (1) the extent of the variant's negative
impact on the gene product, (2) the zygosity of the variant, and (3) the
location of the variant within a gene consistent with the USH subtype.
Variants expected to have a drastic impact on the amino acid sequence
because they either introduced a premature stop codon (nonsense
variants), or modiﬁed the protein sequence, charge, or structure (small
frameshift insertions and deletions, splice-site variants, and missense
variants), were selected for further evaluation. Then, from this
restricted list, the presence of biallelic variants predicted of functional
signiﬁcance was investigated, assessing to this end the zygosity of each
variant and the possibility of two different monoallelic variants within
the same gene (compound heterozygotes). The adequation of the
genetic ﬁndings with the initial clinical diagnosis was checked last.
As a result, biallelic mutations were identiﬁed in 84.8% (362/427) of
the USH patients and monoallelic mutations in an additional 11.7%
(50/427) (Table 1 and Supplementary Tables 1–3). Whenever DNA
from the proband's parents was available (ie, in ~ 45% of the cases),
the familial segregation analysis conﬁrmed the biallelic inheritance of
the mutations (data not shown). Overall, the variants predicted
pathogenic were located in every gene surveyed in the panel, except
CIB2 and DFNB31 (Supplementary Table 4). Notably, 3.5% (15/427)
of the patients remained without a detectable mutation at this stage.
Genome-wide SNP array and gene-focused qPCR analysis identify
large genomic rearrangements in 9% of USH patients
When TES failed to identify the biallelic mutations in a patient, the
patient's genome was tested for possible large genomic rearrangements
by genome-wide SNP array analysis. We ﬁrst queried allelic imbalance
by determining the number of genome copies of 300 000 polymorphic
markers distributed throughout the genome. The indication of gains
or losses of genetic material in the patient's genome was inferred from
the detection of more or fewer SNP copies than expected (see Patients
and Methods for details). CNVs covering three or more consecutive
SNPs were conﬁrmed by qPCR ampliﬁcation of the underlying exons.
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For more ambiguous CNV loci, ie, those identiﬁed by only one or two
consecutive SNPs and those with unclear boundaries, the ampliﬁcation
of the surrounding exons was also carried out. In parallel, a thorough
examination of every exon of the mutation-bearing gene or USH
subtype-matching genes of patients with a partial or no molecular
diagnosis, respectively, was carried out by qPCR ampliﬁcation.
We identiﬁed a total of 43 alleles harboring large DNA rearrange-
ments (38 deletions and ﬁve duplications), which improved the
molecular diagnosis in 60% (39/65) of the USH patients without a
complete diagnosis after TES, adding 7.9% of newly resolved cases to
the 84.8% of previously resolved cases (Figure 1, Table 1, and
Supplementary Table 4). Remarkably, 87% of the large rearrange-
ments identiﬁed in this study were novel (Figure 1, red and green
annotations), a result largely explained by the systematic survey of the
USH gene exons by qPCR whenever genome-wide SNP array analysis
was inconclusive. The latter analysis indeed allowed us to identify 21 of
the rearrangements (which were all conﬁrmed by qPCR), but the
other 22 deletions and insertions were detected only by qPCR analysis
of the complete exon sequence of the genes of interest. Of note, only
four deletions were biallelic, whereas all the other rearrangements were
monoallelic. Segregation analysis was possible for 12 patients and
conﬁrmed the biallelic inheritance of the genetic defects (data not
shown). Also, 26 deletions and four duplications were found in
combination with a monoallelic point mutation. The ﬁve remaining
monoallelic large rearrangements were not associated with any other
detectable mutation.
Therefore, using this three-step strategy to identify both point
mutations and genomic rearrangements in USH-associated genes, we
identiﬁed biallelic mutations in 92.7% (396/427) of the patients
(Table 1 and Supplementary Tables 1–2). This corresponds to a raise
in the efﬁciency of the USH molecular diagnosis by 15–25% compared
with previous studies.22–24 Regarding the 5.8% (25/427) of the USH
patients with as yet incomplete molecular diagnosis (Supplementary
Table 3), we assume that we did not detect the second mutation
because it lies in a region either not surveyed or not captured by our
arrayed PCR techniques. Such regions include introns, promoter
regions and other regulatory regions of the TES-surveyed genes,
genome-wide areas that are free of CNV markers, and possibly a still
unknown USH gene.22,34 In our cohort, only 1.4% (6/427) of the
patients characterized clinically as USH1 (one patient) and USH2 (ﬁve
patients), remain with no molecular diagnosis at the end of the study
(data not shown). In addition to the above-mentioned absence or
inefﬁciency of experimental coverage of genome areas, erroneous
clinical diagnosis because of an atypical phenotype might also explain
the absence of mutations detected in these patients. Finally, we cannot
exclude the possibility that some patients suffer from a non-syndromic
association of deafness and blindness caused by two unrelated sets of
mutations in non-USH genes.
The proportions of the various types of mutations are different
between USH genes
Mutations in USH1 genes were detected in 36% of the USH patients
(154/427) (Table 2). MYO7A mutations were detected in 69.5%
(107/154), CDH23 mutations in 13% (20/154), PCDH15 mutations in
7.8% (12/154), USH1C mutations in 7.1% (11/154), and USH1G
Table 1 Number of patients with biallelic, monoallelic, and no
mutations of functional signiﬁcance in USH genes identiﬁed by the
three techniques (TES, SNP array, and qPCR) used sequentially
 TES SNP array and qPCR TES + SNP array and qPCR 
Biallelic 
mutation 
6934263
Monoallelic 
mutation 
525305
66251noitatumoN
Figure 1 Schematic representation of the large rearrangements identiﬁed at USH loci. Novel rearrangements are represented by red (deletion) or green
(duplication) left-right arrows, and previously reported rearrangements are highlighted in gray. For each rearrangement, the corresponding number of USH
patients from our cohort is indicated between parentheses.
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mutations in 2.6% (4/154) of the USH1 patients. We did not detect
mutations in CIB2. Mutations in USH2 genes were detected in 60.4%
of USH patients (258/427) (Table 2). Mutations in USH2A and
ADGRV1 were detected in 91.5% (236/258) and 8.1% (21/258) of the
USH2 patients, respectively. We did not detect mutations in DFNB31.
Of the total 817 allelic variants identiﬁed in this study, nonsense or
frameshift mutations were detected in 52.1% of the mutated alleles,
missense mutations in 31.5%, splice-site mutations in 9.5%, large
deletions or insertions in 5.3%, synonymous mutations predicted to
result in abnormal splicing in 1%, and in-frame indels and no-stop
mutations in 0.6%. However, the proportion of nonsense, frameshift,
splice, and missense mutations differed from one USH gene to another
(Table 3). This was especially true for the proportion of nonsense
mutations, which ranged between 8.1 and 44.5% depending on the
USH gene: speciﬁcally, 44.5% (4/9) in USH1G, 37.5% (15/40) in
ADGRV1, 31.1% (145/465) in USH2A, 26.9% (56/208) in MYO7A,
26% (6/23) in PCDH15, 19% (4/21) in USH1C, 11.7% (2/17) in
CLRN1, and 8.1% (3/37) in CDH23. The proportion of missense
mutations was even more variable, ranging from 0–46.6% depending
on the USH gene: speciﬁcally, 46.6% (97/208) in MYO7A, 41.1%
(7/17) in CLRN1, 37.8% (14/37) in CDH23, 28.8% (134/465) in
USH2A, 10% (4/40) in ADGRV1, 4.7% (1/21) in USH1C, and 0% in
PCDH15 (0/23) and USH1G (0/8). Finally, large DNA rearrangements
accounted for 2–33.3% of the mutations depending on the gene:
speciﬁcally, 33.3% (3/9) in USH1G, 26% (6/23) in PCDH15, 13.5%
(5/37) in CDH23, 7.5% (3/40) in ADGRV1, 5% (23/465) in USH2A,
and 2% (4/208) in MYO7A. We did not detect any large deletions or
duplications in USH1C, CIB2, DFNB31, or CLRN1.
Remarkably, 213 out of the 421 different mutations identiﬁed
in this study had not been previously reported (Figures 1–3,
Supplementary Table 4). In our cohort of patients, these new variants
represent 40% (MYO7A, USH2A) to 78% (USH1G) of the mutations
identiﬁed in each USH gene.
Table 2 Distribution of the USH patients according to their clinical
subtype and, for each subtype, the affected gene
Clinical subtype Gene Number of patients
USH1 (36%) MYO7A 107 (69.5%)
CDH23 20 (13%)
PCDH15 12 (7.8%)
USH1C 11 (7.1%)
USH1G 4 (2.6%)
USH2 (60.4%) USH2A 236 (91.5%)
ADGRV1 21 (8.1%)
PDZD7 1 (0.4%)
USH3 (2.1%) CLRN1 9
Table 3 Number of variant alleles identiﬁed for each USH gene, and for the different mutation types
The number of variant alleles identiﬁed in the cohort of 427 patients by our combinatorial strategy is indicated for each gene and each mutation type. The bubbles display the proportion of each
mutation type for the corresponding gene. Color code: USH1, blue; USH2 and USH2-associated, pink; USH3, green.
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The geographical distribution of recurrent mutations across Europe
reveals the existence of regionally restricted mutations
Focusing on the mutations present in at least 3% of the patients
carrying mutations in a given USH gene, we mostly found recurrent
point mutations in USH2A, CDH23, and USH1C. The two most
common mutations were USH2A:c.2299delG (p.Glu767Serfs*21) and
USH2A:c.11864G4A (p.Trp3955*). They were detected in ~ 22% of
USH2A patients each (53 and 54 out of 236, respectively), but their
distributions differed greatly from one country to another (insert in
Figure 4 and Table 4). The proportions of USH2A patients carrying
the c.2299delG variant and the c.11864G4A variant were 32.7%
(18/55) and 20% (11/55) in Germany, 28.7% (29/101) and 4.9%
(5/101) in France, 11.1% (4/36) and 11.1% (4/36) in Italy, and 0%
(0/40) and 82.5% (33/40) in Slovenia, respectively. Other recurrent
mutations were detected in USH2A, CDH23, and USH1C throughout
Europe, and are presented in Table 4. Of note, ﬁve recurrent
point mutations were geographically restricted: MYO7A:c.721C4G
(p.Arg241Gly) and USH2A:c.10712C4T (p.Thr3571Met) to Italy,
MYO7A:c.52C4T (p.Gln18*) and PCDH15:c.1103delT (p.Leu368
Trpfs*58) to Slovenia, and USH2A:c.2276G4T (p.Cys759Phe) to
France (3.9% of USH2A patients) (Table 4). The variant MYO7A:
c.721C4G (p.Arg241Gly) had already been reported in Italian
patients35 and the variants USH2A:c.10712C4T (p.Thr3571Met)
and USH2A:c.2276G4T (p.Cys759Phe) had been reported in other
European populations.21,36 The variant MYO7A:c.52C4T (p.Gln18*)
had been previously reported in Japan and Canada,37,38 but
never before in Europe. Finally, the variant PCDH15:c.1103delT
(p.Leu368Trpfs*58), identiﬁed exclusively in Slovenian patients in this
study, had only been found before in the Hutterite population
originating from Moravia.39
We also identiﬁed possibly recurrent large deletions on the basis of
exon loss. We detected a deletion in MYO7A, which encompasses
exon 46, in four patients from three different countries. We also
detected three different deletions in USH2A, encompassing exons 22–
24, exon 20, or exon 60, and a deletion in PCDH15, encompassing its
promoter region and ﬁrst coding exon, in two unrelated patients each.
The characterization of the precise breakpoints of these deletions will
clarify whether they are related to the existence of abnormal
recombination hot spots.
The presence, in a few patients, of mutations in more than one USH
gene calls for thorough molecular diagnosis
We noticed that four patients carried, on top of biallelic mutations in a
given USH gene, an additional deleterious monoallelic variant in a
different USH gene. One patient was homozygous for USH2A:
c.1876C4T (p.Arg626*) and heterozygous for USH1G:c.800G4A
(p.Trp267*). Another patient was a compound heterozygote for
MYO7A:c.3503G4A (p.Arg1168Gln)+deletion of exon 46, and was
heterozygous for USH2A:c.2299delG (p.Glu767Serfs*21). The third
patient, who was a compound heterozygote USH2A:c.9014G4C
(p.Ser3005Thr)+deletion of exon 4, also carried a monoallelic large
duplication encompassing exon 6–37 of CDH23. Finally, the last
patient was homozygous for MYO7A:c.2476G4A (p.Ala826Thr) and
heterozygous for ADGRV1:c.10768A4T (p.Ser3590Cys). This points
to the need to screen all USH and USH-associated genes to avoid
rendering an inaccurate molecular diagnosis, which could compromise
genetic counseling and possibly also gene therapy. However, we did
not ﬁnd compelling genetic evidence for a digenic transmission of the
USH phenotype in any patient of this cohort.
Figure 2 Schematic representation of the proteins encoded by USH1 genes, annotated with the novel variants identiﬁed by TES. For each protein, the
longest isoform is shown, and the novel pathogenic sequence variants are indicated. Abbreviations: IQ, isoleucine-glutamine motifs; MyTH4, myosin tail
homology 4 domain; FERM, band 4.1-ezrin-radixin-moesin domain; SH3, src homology 3 domain; PDZ, PSD95-discs large-ZO1 domain; CC, coiled coil
domain; PST, proline–serine–threonine–rich region; EC, extracellular cadherin domain; TM, transmembrane domain; Ank, ankyrin domain; SAM, sterile alpha
motif domain.
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PDZD7 is a modiﬁer gene of the retinal phenotype in USH2A
patients, and contributes to the digenic inheritance of USH2 with
ADGRV1.4 We did not detect any sequence variants of functional
signiﬁcance in PDZD7 in any of the 236 USH2A patients or of the
three USH2C patients with a monoallelic mutation of ADGRV1.
However, we did identify the PDZD7:c.2806C4T (p.Arg936*) variant
at the heterozygous state in an Italian patient with a clinical diagnosis
of USH2, but this patient did not carry any other sequence variant of
functional signiﬁcance in the USH genes analyzed.
Patients clinically diagnosed as USH2 may carry mutations in USH1
genes
Our cohort consisted of 139 and 282 patients classiﬁed as USH1 and
USH2 on clinical criteria, respectively, and six unclassiﬁed patients. On
the other side, the molecular analysis gave the following distribution of
biallelic or monoallelic mutations in USH genes: 154 USH1, 258
USH2, and 9 USH3. This evidenced a genotype-phenotype discre-
pancy in 13 patients initially classiﬁed as USH2 (marked with a # next
to their ID code in Supplementary Tables 1 and 3), who turned out to
carry biallelic mutations in USH1 genes: speciﬁcally, CDH23 (seven
patients), MYO7A (ﬁve patients), and USH1C (one patient). This
indicates that mutations in these genes can lead to phenotypes that
cross the boundaries between the USH clinical subtypes. In fact, there
does not appear to be a straightforward correlation between the
severity of the USH phenotype, especially that of the hearing
impairment, and the type of mutations identiﬁed in these genes. In
addition, eight of the nine patients carrying mutations in the USH3
gene had been classiﬁed as USH2 on clinical criteria, and the last one
was unclassiﬁed. Incidentally, the remaining ﬁve patients initially
unclassiﬁed carried mutations in USH1 genes (three patients) or
USH2 genes (two patients).
Comparison of this strategy with previous strategies for the
molecular diagnosis of USH
Technical improvements for the molecular diagnosis of USH have
been recently reported. Besnard et al.23 used massively parallel targeted
sequencing and found biallelic mutations in 77% (10/13) of European
patients. Bujakowska et al.40 performed selective exon capture,
followed by NGS and CGH array analysis, but surprisingly, detected
biallelic mutations in barely a third (29.7%) of the 47 USH1 patients
tested. Krawitz et al.22 used targeted enrichment and deep sequencing
of USH exons and identiﬁed biallelic mutations in 79% (35/44) of the
patients. Likewise, Aparisi et al.24 identiﬁed biallelic mutations in 68%
(22/32) of USH patients. The strategy described here allowed us to
raise the overall diagnostic effectiveness by 15–25%, compared with
these studies. Arrayed PCR-based TES provided an excellent coverage
Figure 3 Schematic representation of the proteins encoded by USH2 genes and PDZD7, annotated with the novel variants identiﬁed by TES. For each
protein, the longest isoform is shown, and the novel pathogenic sequence variants are indicated. LamG/TspN/PTX, N-terminal thrombospondin/pentaxin/
laminin G-like domain; Lam Nter, laminin N-terminal domain; Lam EGF-like, laminin-type EGF-like domain; LamG-like, laminin G-like domain; FNIII,
ﬁbronectin type III domain; TM, transmembrane domain; Calx, Ca2+-binding calcium exchanger β; EAR, Epilepsy Associated Repeats; PDZ, PSD95-discs
large-ZO1 domain; GPS, G-protein-coupled proteolysis site.
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of the exons analyzed, and the use of qPCR to detect large genomic
rearrangements that could not be identiﬁed by TES was very efﬁcient.
Indeed, using qPCR, we not only conﬁrmed 21 deletions or insertions
found by SNP array analysis, but also uncovered 23 additional
rearrangements that were overlooked by the genome-wide SNP array
analysis. Previous studies had led to the identiﬁcation of large deletions
or duplications in USH2A and PCDH15, but always on relatively small
cohorts of USH patients.22,41–43 The strategy used in this study allowed
us to identify large deletions or duplications not only in USH2A and
PCDH15, but also in CDH23, MYO7A, ADGRV1, and USH1G
(Figure 1), bringing the total to 43 rearrangements present in 9.1%
(39 out of 427) of the patients studied.
Figure 4 Prevalence and European distribution of the mutations of USH1, USH2, and USH3 genes identiﬁed in this study. For each participating country,
the pie chart is equally divided in 11 sectors, representing each of the different USH1 (blue), USH2 (pink, and dark pink for the USH2 modiﬁer PDZD7),
and USH3 (green) genes. In each sector, the colored area indicates the proportion of the USH1 patients, or the proportion of the USH2 and USH3 patients,
carrying mutations in the corresponding gene. The inset illustrates the proportion of three prevalent USH2A mutations relative to the total number of USH2A
mutations identiﬁed, in France, Germany, Italy, and Slovenia.
Table 4 Recurrent mutations in USH1 genes and USH2A
Denmark France Germany Italy Slovenia Spain
MYO7A:c.52C>T; p.(Gln18*) 0 49 11 18 12 6
17
MYO7A:c.721C>G; p.(Arg241Gly) 5
USH1C:c.238dup; p.(Arg80Profs*89) 0 5 1
3
1
2
2
1
1
0
CDH23:c.2289+1G>A
0 11
1
2
1
2 3
3
2
PCDH15:c.1103delT;p.(Leu368Trpfs*58) 0 5 1 1 4     4
1
USH2A:c.2276G>T; p.(Cys759Phe)
3 101
4
55 36 40 1
USH2A:c.2610C>A; p.(Cys870*) 1 3 7
USH2A:c.2299delG; p.(Glu767Serfs*21) 1 29 18 4 1
USH2A:c.7595-2144A>G 7 1 1
USH2A:c.10712C>T; p.(Thr3571Met) 10
USH2A:c.11864G>A; p.(Trp3955*) 5 11 4 33
Each bubble indicates the number of patients per country carrying the recurrent mutation (color code: USH1, blue; USH2, pink). The number in the far left corner of each cell indicates the total
number of patients carrying variant alleles of the corresponding gene.
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In conclusion, the combined use of two distinct approaches aiming
at the identiﬁcation, on the one hand, of small nucleotide variations,
using an arrayed PCR-based technique and high-throughput DNA
sequencing, and on the other hand, of large genomic rearrangements,
using the SNP array technique coupled with exon-speciﬁc qPCR
analysis, substantially improved the quality of the molecular diagnosis
of USH, resulting in the highest diagnostic yield ever obtained, on the
largest cohort of USH patients studied to date.
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